Montreux, Switzerland | April 4, 2023 – MedXCell SA, a European venture builder that specializes in cell therapy for major diseases such as cancer, autoimmune, neurological, and degenerative diseases, is pleased to announce that its paper “Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody” has been published in the International Journal of Pharmaceutics and is now accessible online here.
Using the best candidate functional excipient, MedXCell was able to demonstrate successful delivery of a SARS-CoV-2 neutralizing monoclonal antibody into the entirety of the respiratory tract of experimental mice, with concomitant prophylactic and post-exposure protection from SARS-CoV-2 pathology.
ABOUT MEDXCELL
MedXCell identifies or initiates commercially viable research projects with academic institutions and
develops and supports them through a co-design phase, which can help to drastically reduce project
risks before the creation of the start-up. Based on the outcome of this phase, MedXCell creates a new
entity that is well-prepared for independent financing or establishes an early strategic partnership.
For more information, please contact:
This website contains information about products that may not be available in all countries, available under different trademarks or for different indications. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development and described on this site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider
© All rights reserved 2022 – MedXCell SA